Quick overview

---

Hims & Hers Health, Inc. (HIMS) has established itself as a disruptive force by emphasizing both technological innovation and customer engagement.  The company’s valuation has been criticized, with a forward P/E ratio of 83.89 and a market capitalization of $11 billion.

 

This analysis assesses whether its ambitious growth projections and recent customer-centric initiatives—such as the Community Member Council and Health Collective—justify its premium pricing in comparison to industry benchmarks.

Members of The Health Collective, an app-based ambassador program, can participate in peer support networks, access early product trials, and share their health journeys.

The Community Member Council, comprising 15 carefully selected members, provides direct input to inform platform enhancements and product development.

The financial outlook for Hims and Hers in 2025 is extremely ambitious. According to a Nasdaq note, analysts predict full-year revenue of $2.35 billion (up 59.39 percent YoY) and Q3 2025 earnings of $0.09 per share (up 50% YoY). As previously mentioned in the Nasdaq coverage, the company’s expansion into high-growth categories like menopause care and AI-driven treatment programs is the foundation for its 2026 revenue target of $2.08 billion and its 2030 target of $6.05 billion.

The company’s ability to scale profitably is demonstrated by its $193.60 million net income in the most recent year and its projected 118.52 percent EPS growth for 2025, according to StockAnalysis data.  Hims & Hers’ valuation metrics seem out of line in comparison to industry averages.

According to the S&P 500 Health Care P/E, its forward P/E ratio of 83.89 is higher than the healthcare sector’s Q3 2025 average of 24.87, and its PEG ratio of 3.42 is based on Zacks’ 118.5 percent EPS growth estimate mentioned in the Nasdaq note.